View Future Growth20/20 Biolabs 過去の業績過去 基準チェック /0620/20 Biolabsの収益は年間平均-50.7%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間15.3% 28.5%割合で 減少しています。主要情報-50.73%収益成長率-49.90%EPS成長率Medical Equipment 業界の成長8.90%収益成長率-28.52%株主資本利益率-186.76%ネット・マージン-276.19%前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • 7hBiolabs, Inc. Announces Non-Compliance with Nasdaq Listing RuleOn July 17, 2026, 20/20 Biolabs, Inc. received a written notification from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with the $1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days from June 3, 2026 to July 16, 2026. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until January 13, 2027, to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for at least ten consecutive business days during the 180-calendar day compliance period. In the event that the Company is not in compliance by January 13, 2027, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to cure the deficiency and regain compliance with the Bid Price Rule within the compliance period(s) under Nasdaq's Listing Rules.お知らせ • Jun 0220/20 Biolabs, Inc., Annual General Meeting, Aug 18, 202620/20 Biolabs, Inc., Annual General Meeting, Aug 18, 2026.お知らせ • May 1620/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).お知らせ • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.お知らせ • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.収支内訳20/20 Biolabs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:AIDX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 262-54131 Dec 252-43130 Sep 252-33130 Jun 252-44131 Mar 252-54131 Dec 242-65130 Sep 242-65130 Jun 242-54131 Mar 241-64231 Dec 231-65130 Sep 232-65130 Jun 233-55131 Mar 237-24031 Dec 221123030 Sep 221443030 Jun 221762031 Mar 221442031 Dec 211023030 Jun 190-22031 Mar 190-22031 Dec 180-11030 Sep 180-11030 Jun 180-11031 Mar 180-11031 Dec 170-11030 Sep 170-11030 Jun 170-11031 Mar 170-22031 Dec 160-22031 Dec 151-221質の高い収益: AIDXは現在利益が出ていません。利益率の向上: AIDXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AIDXは利益が出ておらず、過去 5 年間で損失は年間50.7%の割合で増加しています。成長の加速: AIDXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AIDXは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 14.8% ) と比較することは困難です。株主資本利益率高いROE: AIDXは現在利益が出ていないため、自己資本利益率 ( -186.76% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 07:58終値2026/07/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋20/20 Biolabs, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael OkunewitchMaxim Group
お知らせ • 7hBiolabs, Inc. Announces Non-Compliance with Nasdaq Listing RuleOn July 17, 2026, 20/20 Biolabs, Inc. received a written notification from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with the $1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days from June 3, 2026 to July 16, 2026. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until January 13, 2027, to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for at least ten consecutive business days during the 180-calendar day compliance period. In the event that the Company is not in compliance by January 13, 2027, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to cure the deficiency and regain compliance with the Bid Price Rule within the compliance period(s) under Nasdaq's Listing Rules.
お知らせ • Jun 0220/20 Biolabs, Inc., Annual General Meeting, Aug 18, 202620/20 Biolabs, Inc., Annual General Meeting, Aug 18, 2026.
お知らせ • May 1620/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).
お知らせ • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.
お知らせ • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.